APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

BACKGROUND Two independent coding variants in the apolipoprotein L1 gene (APOL1), G1 and G2, strongly associate with nephropathy in African Americans; associations with cardiovascular disease are more controversial. Although APOL1 binds plasma high-density lipoproteins (HDLs), data on APOL1 risk variant associations with HDL subfractions are sparse. METHODS Two APOL1 G1 single nucleotide polymorphisms and the G2 insertion/deletion polymorphism were genotyped in 2010 Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study participants with nuclear magnetic resonance spectroscopy-based lipoprotein subfraction measurements. Linear regression was used to model associations between numbers of APOL1 G1/G2 risk variants and HDL subfractions, adjusting for demographic, clinical and ancestral covariates. RESULTS Female sex and higher percentage of African ancestry were positively associated with the number of APOL1 G1/G2 risk alleles. In the unadjusted analysis, mean (standard error) small HDL concentrations (μmol/L) for participants with zero, one and two G1/G2 risk alleles were 19.0 (0.2), 19.7 (0.2) and 19.9 (0.4), respectively (P = 0.02). Adjustment for age, sex, diabetes and African ancestry did not change the results but strengthened the statistical significance (P = 0.004). No significant differences in large or medium HDL, very low-density lipoprotein or low-density lipoprotein particle concentrations were observed by APOL1 genotype. CONCLUSIONS Greater numbers of APOL1 G1/G2 risk alleles were associated with higher small HDL particle concentrations in African Americans. These results may suggest novel areas of investigation to uncover reasons for the association between APOL1 risk variants with adverse outcomes in African Americans.

[1]  M. Rocco,et al.  Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial , 2014, Kidney international.

[2]  Nicholette D. Palmer,et al.  APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes , 2014, Kidney international.

[3]  P. Joshi,et al.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. , 2015, European heart journal.

[4]  J. Tardif,et al.  HDL and cardiovascular risk: is cholesterol in particle subclasses relevant? , 2015, European heart journal.

[5]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[6]  S. Martin,et al.  High-density lipoprotein subfractions: current views and clinical practice applications , 2014, Trends in Endocrinology & Metabolism.

[7]  E. Schaefer,et al.  High-density lipoprotein metabolism, composition, function, and deficiency , 2014, Current opinion in lipidology.

[8]  O. Gribouval,et al.  APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  S. Gabriel,et al.  Increased Burden of Cardiovascular Disease in Carriers of APOL1 Genetic Variants , 2014, Circulation research.

[10]  N. Paynter,et al.  High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease , 2014, Circulation. Cardiovascular quality and outcomes.

[11]  Barry I. Freedman,et al.  APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.

[12]  M. Fornage,et al.  APOL1 variants associate with increased risk of CKD among African Americans. , 2013, Journal of the American Society of Nephrology : JASN.

[13]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[14]  M. Rocco,et al.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[16]  E. Schaefer,et al.  Metabolic and functional relevance of HDL subspecies , 2011, Current opinion in lipidology.

[17]  D. English,et al.  NMR-determined lipoprotein subclass profile is associated with dietary composition and body size. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  S. Jee,et al.  Relationship between HDL3 subclasses and waist circumferences on the prevalence of metabolic syndrome: KMSRI-Seoul Study. , 2010, Atherosclerosis.

[19]  C. Winkler,et al.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. , 2010, Journal of the American Society of Nephrology : JASN.

[20]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[21]  P. Barter,et al.  Effects of High-Density Lipoproteins on Pancreatic &bgr;-Cell Insulin Secretion , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[22]  P. Ridker,et al.  Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women , 2010, Diabetes.

[23]  David H. Alexander,et al.  Fast model-based estimation of ancestry in unrelated individuals. , 2009, Genome research.

[24]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[25]  C. Parikh,et al.  Screening for kidney diseases: older measures versus novel biomarkers. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[26]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[27]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[28]  C. Moy,et al.  The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design , 2005, Neuroepidemiology.

[29]  Ken Williams,et al.  Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study , 2005, Circulation.

[30]  D. Lackland,et al.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. , 2003, Kidney international.

[31]  R. Brasseur,et al.  Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.

[32]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[33]  D. Freedman,et al.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Duchateau,et al.  Apolipoprotein L, a New Human High Density Lipoprotein Apolipoprotein Expressed by the Pancreas , 1997, The Journal of Biological Chemistry.

[35]  D. Sviridov,et al.  Altered properties of high density lipoprotein subfractions in obese subjects. , 1997, Journal of lipid research.

[36]  R. Krauss,et al.  Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. , 1992, Clinical chemistry.

[37]  N. Golden,et al.  in Women with , 1992 .

[38]  D W Bennett,et al.  Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. , 1991, Clinical chemistry.